Massive BioMassive Bio Facebook ad: “PD-L1 High NSCLC Trial”
Running for 54 days since August 7, 2026. Crush last saw it on September 30, 2026.
Run by Massive Bio on Facebook. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 1563177488776234
- Platforms
- Facebook, Instagram, Audience Network, Messenger and Threads
- Relaunches
- 0
Ad text
For metastatic NSCLC with PD-L1 ≥50% and no actionable mutations, a first-line clinical trial is open. Refer appropriate patients today.
Where the ad sends people
massivebio.com
PD-L1 High NSCLC Trial
PD-L1 ≥50% | No actionable mutations | Treatment-naive advanced NSCLC.'
Learn more: massivebio.com(opens in a new tab)
